Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Sanofi – Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia. The safety profile w
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1383931917-16f7e81b08344140b4041462de226112.jpg "The 6 Best Online Banks for May 2024")
